Amolyt Pharma
Michel Ovize serves as a Senior Medical Director at Amolyt Pharma since September 2020, bringing extensive expertise to the role. Concurrently, Michel Ovize has held the title of PUPH at Hospices Civils de Lyon since October 1985, contributing to the organization's medical leadership for several decades.
This person is not in any offices
Amolyt Pharma
Amolyt Pharma specializes in peptides for the treatment of rare endocrine and metabolic disorders. Its programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism, and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism.